6 Comments
User's avatar
Joseph Deniakis's avatar

Where to buy this security?

Expand full comment
Penny Queen's avatar

This is on the OTC as $TREIF, on the Canadian stock exchange as $TRUE, and 939 on German exchanges

Expand full comment
krista zander's avatar

Great article PQ I’ve been following #TREIF since you first alerted it 🙏

Expand full comment
Penny Queen's avatar

Well, i want expecting a 30% run in the first 15 minutes, but I'm glad people see the value here. I believe the company has everything they need to be successful.

Expand full comment
Ahtsham Ahmad's avatar

how would the market react as per your experience? as net profit would still be negative 4-5m. market follows EPS in the long run, 24-->100m, means it will show 4x profit. Do we have Rocket Doctor bottom profit numbers or only revenue . we dont how much cost rocket doctor will have which will come here in consolidated financials? just by looking at 1 revenue side, but forgetting cost, would be half picture?

Expand full comment
Penny Queen's avatar

sorry I missed this question Ahtsham! I totally get where you’re coming from. In small caps like this, the market doesn’t always wait for perfect EPS; it tends to react to perceived potential first and then adjusts once the financials catch up. That’s part of what makes them high-risk, high reward.

Right now, we only have revenue numbers for Rocket Doctor, no detailed cost breakdown yet ....so, yeah, any model without that is half a picture. The upcoming August financials should give us a better sense of what consolidated margins look like post-acquisition.

If they can demonstrate ARR growing several times over and show clear progress toward cutting losses, the market could start to re-rate the story even before they hit net profitability. Until we see Rocket Doctor’s cost side, though, it’s really about weighing that upside potential against the execution risk.

XO

Penny

Expand full comment